Pancreatic Cancer Market Size (2024 – 2030)

The Pancreatic Cancer Market was valued at USD 2,125.57 million in 2023. Over the forecast period of 2024-2030, it is projected to reach USD 5157.59 million by 2030, growing at a CAGR of 13.5%.

Pancreatic cancer stands as one of the most frequently encountered malignancies and ranks seventh in terms of cancer-related mortality worldwide. Its incidence is notably higher in Western nations. The prevalence of pancreatic adenocarcinoma is on the rise in developed regions, with modifiable lifestyle factors such as alcohol consumption and obesity potentially exerting significant influence.

Key Market Insights:

The onset of pancreatic cancer occurs when abnormal cells within the pancreas undergo uncontrolled proliferation and division, forming a tumor. The normal functioning of the pancreas is compromised in the presence of malignancies. Statistics indicate a higher incidence and mortality rate among men compared to women for this type of cancer. Symptoms of pancreatic cancer include abdominal pain, weight loss, diarrhea, jaundice, and blood clots, among others, resulting from abnormal cell growth. Smoking stands as the primary risk factor associated with pancreatic cancer, with other risk factors including pancreatitis, obesity, family history of the disease, and advanced age.

Treatment approaches for pancreatic cancer are contingent upon various factors including the cancer's stage and location, alongside the patient's overall health and preferences. As the disease advances, symptom management assumes greater importance, albeit these interventions may yield limited benefits during later stages of the illness.

The pancreatic cancer market size is anticipated to be propelled by increased rates of obesity, alcohol consumption, and smoking addiction. Pancreatic cancer often presents at later stages, characterized by symptoms such as unintentional weight loss and persistent loss of appetite among patients. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, tailored to the individual patient's condition.

Pancreatic Cancer Market Drivers:

The chemotherapy segment is anticipated to command a significant share and drive market growth.

Chemotherapy serves as a primary modality in cancer treatment, targeting pancreatic cancer cells by impeding their growth and division processes. These drugs operate systemically, circulating through the bloodstream to eradicate cancer cells throughout the body. However, chemotherapy can inadvertently harm healthy cells, leading to significant side effects. Its therapeutic effects may encompass the reduction and inhibition of pancreatic tumor growth.

According to the American Cancer Society, chemotherapy drugs employed in pancreatic cancer treatment include Gemcitabine (Gemzar), 5-fluorouracil (5-FU), Irinotecan (Camptosar), Oxaliplatin (Eloxatin), Albumin-bound paclitaxel (Abraxane), Capecitabine (Xeloda), Cisplatin, Paclitaxel (Taxol), Docetaxel (Taxotere), and Irinotecan liposome (Onivyde).

Since the 1990s, gemcitabine (Gemzar) has stood as the cornerstone of treatment for resectable pancreatic cancer, typically administered as adjuvant chemotherapy following surgical intervention, such as the Whipple procedure, despite its taxing nature. More recently, gemcitabine has been paired with capecitabine (Xeloda) in some cases. Chemotherapy may be employed in isolation or combination with surgery, targeted therapy, immunotherapy, and/or radiation. When administered alongside radiation therapy, chemotherapy is often given at a lower dosage. Fluorouracil (5-FU) is the preferred chemotherapy agent in conjunction with radiation therapy due to its extensive usage experience and fewer associated side effects.

An increasing number of geriatric populations drives the market.

The increasing geriatric population is projected to drive the expansion of the market. Given their compromised immune systems, the elderly are more susceptible to pancreatic cancer and its treatment, thereby further augmenting the market's growth rate.

Moreover, initiatives by both public and private organizations aimed at raising awareness and advancements in molecular biology are expected to contribute to the expansion of the pancreatic cancer treatment market. Additionally, the growing prevalence of smoking addiction and tobacco consumption is anticipated to lead to an expansion of the market for pancreatic cancer treatment.

Pancreatic Cancer Market Restraints and Challenges:

The escalating expenses associated with drug development and treatment, coupled with the imposition of stringent regulatory guidelines, are poised to impede market growth. Over the projected time frame, the market will encounter obstacles stemming from these challenges. However, innovative inventions and comprehensive authorization methods hold the potential to surmount these barriers and drive forward the advancement of the global pancreatic cancer market.

Pancreatic Cancer Market Opportunities:

Additionally, the market's expansion is bolstered by a surge in research and development endeavors, offering favorable prospects for the growth of the pancreatic cancer treatment market. Furthermore, the uptick in drug approvals and launches is poised to accelerate the market's growth trajectory. Moreover, increased investment in the advancement of cutting-edge technologies and the emergence of new markets will further present advantageous opportunities for the growth of the pancreatic cancer treatment market during the forecast period.

PANCREATIC CANCER MARKET REPORT COVERAGE:

Pancreatic Cancer Market Segmentation - By Treatment Type

• Chemotherapy

• Immunotherapy

• Hormone Therapy

• Surgery

• Radiation Therapy

• Targeted Drug Therapy

• Others

Treatment-type segments such as surgery and radiology are anticipated to maintain dominance in the market across the forecast period. This supremacy can be attributed to the prominence of targeted drugs and innovative biological therapeutics within this segment. Moreover, the advancement of personalized treatment systems is further contributing to the segment's growth trajectory.

Pancreatic Cancer Market Segmentation - By Cancer Type

• Endocrine Pancreatic Cancer

• Exocrine Pancreatic Cancer

The Exocrine segment emerges as the largest market segment, primarily due to the pancreas being predominantly composed of exocrine cells compared to endocrine cells in the body. This composition is expected to propel the growth of the segment. The increasing prevalence of exocrine tumors is a significant factor contributing to the growth of this segment. Exocrine cancer, which affects the exocrine cells of the pancreas, particularly through cancerous growth in the ducts, is anticipated to be a key driver of market growth worldwide.

Pancreatic Cancer Market Segmentation - By End User

• Hospitals

• Clinics

• Diagnostic Laboratories

• Research Institutes

• Research Laboratories

• Others

The Hospital segment continues to maintain its status as the most profitable segment in the global pancreatic cancer therapeutics market, a trend expected to persist throughout the forecast period. This dominance is primarily attributed to the rapid influx of patients seeking treatment in hospitals, facilitated by the presence of skilled medical practitioners and the availability of comprehensive medical systems. Furthermore, hospitals boast robust infrastructure and extensive networks, factors that significantly contribute to the ongoing growth of the market.

Pancreatic Cancer Market Segmentation- by Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East & Africa

The North American pancreatic cancer market has maintained its dominance in the global market, primarily due to the higher prevalence of pancreatic cancer in North American countries, particularly the USA, which has the highest number of cancer cases worldwide. North America accounted for the largest share of revenue in the pancreatic cancer treatment market. This is attributed to the advanced healthcare infrastructure, widespread adoption of pancreatic treatment modalities, and a large target population. Moreover, the rising incidence of pancreatic cancer is driving the demand for treatment options in the region.

On the other hand, the Asia-Pacific pancreatic cancer market is poised to exhibit the most rapid growth globally. The region is expected to witness the fastest expansion during the forecast period. This growth can be attributed to the presence of well-established clinics and critical care centers, along with a significant population affected by pancreatic cancer, contributing to industry development in the Asia-Pacific region. Additionally, with the increasing number of pancreatic cancer cases in Asia-Pacific, the diagnosis and treatment of pancreatic cancer are expected to adhere to similar protocols as those in Western nations.

COVID-19 Pandemic: Impact Analysis

The outbreak of COVID-19 has indeed had a profound impact on hospital and healthcare services, thereby influencing the pancreatic cancer therapeutics and diagnostics market. The global economy has faced considerable repercussions due to the pandemic, resulting in substantial disruptions in the delivery of general hospital care for non-COVID-19 patients.

Latest Trends/ Developments:

• In December 2022, a groundbreaking development occurred as scientists unveiled the world's first early pancreatic cancer screening test, utilizing worms to detect tumors. Initiated in Japan, this test boasts a claimed accuracy rate of 100% in detecting cancer and can identify it in its early stages.

• In December 2022, the FDA approved pelareorep, developed by Oncolytics Biotech® Inc., in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, alongside the chemotherapeutic agents gemcitabine and nab-paclitaxel. This approval is intended for the diagnosis of advanced or metastatic pancreatic ductal adenocarcinoma (TSX: ONC).

• In January 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to multitargeted T-cell therapy MT-601, developed by Marker Therapeutics, for the treatment of pancreatic cancer. MT-601 consists of autologous, non-gene-edited T-cell treatment targeting cancer cells' surface proteins PRAME, SSX2, MAGEA4, NY-ESO-1, and Survivin.

Key Players:

These are the top 10 players in the Pancreatic Cancer Market: -

1. F. Hoffmann-La Roche Ltd. (Switzerland)

2. Sun Pharmaceutical Industries Ltd. (India)

3. Mylan N.V. (US)

4. Pfizer Inc. (US)

5. Teva Pharmaceutical Industries Ltd. (Israel)

6. Novartis AG (Switzerland)

7. Sanofi (France)

8. Zydus Cadila (India)

9. GlaxoSmithKline plc (UK)

10. Johnson & Johnson (US)